Biomarkers in chronic kidney disease: a review (Q37893446)

24 August 2017

1 reference

title

Biomarkers in chronic kidney disease: a review (English)

1 reference

chronic renal insufficiency

24 August 2017

0 references

1 reference

inferred from title

author

Sree K Venuthurupalli

Sree K Venuthurupalli

2

0 references

Matthew A. Cooper

Matthew A Cooper

5

0 references

Wendy E. Hoy

Wendy E Hoy

6

0 references

Jeff S Coombes

Jeff S Coombes

4

0 references

author name string

Robert G Fassett

1

1 reference

PubMed ID

21697815

24 August 2017

Glenda C Gobe

3

1 reference

PubMed ID

21697815

24 August 2017

language of work or name

English

0 references

publication date

22 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

80

1 reference

24 August 2017

806-821

1 reference

24 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2011.198

24 August 2017

0 references

cites work

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Combining GFR and albuminuria to classify CKD improves prediction of ESRD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Proteomic approaches for discovering biomarkers of diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Application of proteomic analysis to the study of renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Common sense approaches to urinary biomarker study design.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Finding new sea legs for urine proteomics

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Cardiovascular risk factors in predialysis patients: Baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Risk factors for chronic kidney disease in Japan: a community-based study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Effect of chronic kidney disease and comorbid conditions on health care costs: A 10-year observational study in a general population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum cystatin C as an endogenous marker of the renal function--a review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum cystatin C as a marker of glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Relationship of uric acid with progression of kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Uric acid: a novel mediator and marker of risk in chronic kidney disease?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Renal risk scores: progress and prospects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Expression of Neutrophil Gelatinase–Associated Lipocalin in Atherosclerosis and Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The origin of multiple molecular forms in urine of HNL/NGAL.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Identification of Neutrophil Gelatinase-Associated Lipocalin as a Novel Early Urinary Biomarker for Ischemic Renal Injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in adult critically ill patients: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Lipocalin 2 is essential for chronic kidney disease progression in mice and humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum and urinary neutrophil gelatinase-associated lipocalin levels in children with chronic renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary neutrophil gelatinase-associated lipocalin: A potential biomarker for predicting rapid progression of drug-induced chronic tubulointerstitial nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Tubular kidney injury molecule-1 (KIM-1) in human renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary N-acetyl-beta-D-glucosaminidase in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Diagnostic value of urinary alanine aminopeptidase and N-acetyl-beta-D-glucosaminidase in comparison to alpha 1-microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary excretion of liver fatty acid-binding protein in health-check participants

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary fatty acid–binding protein as a new clinical marker of the progression of chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Tenascin is an ubiquitous extracellular matrix protein of human renal interstitium in normal and pathologic conditions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary sediment podocalyxin in children with glomerular diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Atrial natriuretic peptides in pathophysiological diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The clinical relevance of adrenomedullin: a promising profile?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

N-terminal pro-brain natriuretic peptide A new gold standard in predicting mortality in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Biochemical detection of left-ventricular systolic dysfunction.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Association between renal insufficiency and malnutrition in older adults: results from the NHANES III.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Kidney dysfunction, inflammation, and coronary events: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Biomarkers of inflammation and progression of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The relation of C--reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Increased risk of chronic kidney disease in elderly with metabolic syndrome and high levels of C-reactive protein: Kahrizak Elderly Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

CRP polymorphisms and progression of chronic kidney disease in African Americans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary interleukin-18 is a marker of human acute tubular necrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Biomarkers in acute and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The transforming growth factor beta system in kidney disease and repair: recent progress and future directions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary transforming growth factor-beta 1 in membranous glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

CD14 : a candidate biomarker for the prognosis of polycystic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Renal CD14 expression correlates with the progression of cystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Regulation of fibroblast growth factor-23 in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Novel regulators of phosphate homeostasis and bone metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

A novel serum protein similar to C1q, produced exclusively in adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Advanced oxidation protein products as a novel marker of oxidative stress in uremia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Oxidative stress is progressively enhanced with advancing stages of CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Oxidative stress and cellular stress response in diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum gamma-glutamyltransferase and risk of disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Is serum gamma glutamyltransferase a marker of oxidative stress?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Association between serum gamma-glutamyltransferase and chronic kidney disease among US adults

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Cystatin C and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Elevated brain natriuretic peptide is associated with abnormal heart geometry in children with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Asymmetrical dimethylarginine: the Uber marker?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibrinogen as a risk factor for stroke and myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibrinogen and risk of cardiovascular disease. The Framingham Study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Leukocyte activation in atherosclerosis: correlation with risk factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

FGF23: fashion or physiology?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Cardiac troponins and renal function in nondialysis patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Inflammation, atherosclerosis, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

CD14++CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Monocyte heterogeneity in obesity and subclinical atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Relationships between birthweight and biomarkers of chronic disease in childhood: Aboriginal Birth Cohort Study 1987-2001.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.198

7 January 2021

Identifiers

DOI

10.1038/KI.2011.198

1 reference

24 August 2017

1 reference

PubMed ID

21697815